{"url_path":"/sec/vtgn/8-k/2026-05-08/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1411685/0001628280-26-032935-index.html","accession_number":"0001628280-26-032935","cik":"0001411685","ticker":"VTGN","issuer_name":"Vistagen Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1411685/0001628280-26-032935-index.html","primary_entity_key":"0001411685","primary_entity_name":"Vistagen Therapeutics, Inc."},"word_count":75,"has_tables":true,"body_markdown":"Item 8.01 Other Events.\n\nOn May 8, 2026, Vistagen Therapeutics, Inc. (the “Company”) issued a press release to announce, among other things, that the last patient has completed their last visit in the randomized, double-blind, placebo-controlled portion of PALISADE-4, the Company’s Phase 3 clinical trial evaluating fasedienol nasal spray for the acute treatment of social anxiety disorder. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1."}